12 citations
,
January 2020 in “touchREVIEWS in Endocrinology” Testosterone may both worsen and protect against COVID-19 effects in men.
15 citations
,
December 2020 in “Pharmacology Research & Perspectives” Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
34 citations
,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
30 citations
,
February 2021 in “Journal of Medical Virology” TMPRSS2 affects COVID-19 severity and treatment options.
6 citations
,
September 2020 in “Journal of The American Academy of Dermatology” Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.
14 citations
,
July 2021 in “Reviews in endocrine and metabolic disorders” SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
4 citations
,
June 2025 in “Medeniyet Medical Journal” TMPRSS2 is crucial for COVID-19 infection and is a potential target for treatment.
77 citations
,
July 2020 in “European Journal of Clinical Pharmacology” Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.
5 citations
,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
38 citations
,
January 2020 in “Cell Transplantation” Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.
228 citations
,
January 2021 in “Journal of Neuroimmune Pharmacology” Men have more severe COVID-19 outcomes than women.
5 citations
,
December 2021 in “Scientific Reports” Age affects how certain proteins involved in COVID-19 infection are expressed in mice, but sex hormones and heart injury do not.
59 citations
,
October 2020 in “Stem Cell Reviews and Reports” Men have higher COVID-19 mortality rates than women due to biological and lifestyle factors.
176 citations
,
May 2020 in “Dermatologic Therapy” COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.
121 citations
,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
82 citations
,
June 2020 in “Inflammation Research” Skin problems in COVID-19 patients are rare and may be due to the body's complex immune response or blood clotting issues.
58 citations
,
December 2020 in “Mayo Clinic Proceedings” The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.
42 citations
,
June 2020 in “Seminars in Oncology” Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
36 citations
,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.
1 citations
,
September 2020 in “Journal of the Endocrine Society” Men have worse COVID-19 outcomes than women due to genetic and hormonal differences.
December 2022 in “International Journal of Biomedicine” Androgens may worsen COVID-19 and hair loss could indicate the disease's severity.
123 citations
,
May 2020 in “Drug Development Research” Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
80 citations
,
June 2020 in “Dermatopathology” COVID-19 can cause various skin lesions, which may result from the virus and immune response, and are not directly linked to illness severity.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
23 citations
,
February 2021 in “Journal of Endocrinological Investigation” Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
21 citations
,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
17 citations
,
May 2021 in “Journal of Assisted Reproduction and Genetics” COVID-19 may harm male fertility and damage the reproductive system.
16 citations
,
August 2021 in “Tumor Biology” TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.